Clinical Trials Browser

Phase 1 × Advanced Solid Tumor × 90 days × Clear all

NCT06233942 2026-06-05

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Phase 1 Recruiting

308 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07408258 2026-06-04

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

Phase 1 Not yet recruiting

20 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05981703 2026-06-03

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Recruiting

217 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06589596 2026-06-03

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

Phase 1 Recruiting

525 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07226349 2026-06-03

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

Phase 1 Recruiting

105 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07414836 2026-06-03

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

Phase 1 Recruiting

84 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06598800 2026-05-29

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

Phase 1 Recruiting

153 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06625593 2026-05-29

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Phase 1 Recruiting

168 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04855656 2026-05-28

MYTHIC

Phase 1 Recruiting

464 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07128303 2026-05-26

Study of GS-5319 in Adults With Solid Tumors

Phase 1 Recruiting

178 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05329103 2026-05-15

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

65 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05901285 2026-05-14

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

48 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07182591 2026-05-14

A Study of DS5361b in Participants With Advanced Solid Tumors

Phase 1 Recruiting

192 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07582822 2026-05-13

JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC

Phase 1 Not yet recruiting

60 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05824663 2026-05-04

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

Phase 1 Completed

17 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05300048 2026-04-30

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Phase 1 Terminated

34 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05687682 2026-04-28

Safety of AM-928 Infusion in Advanced Solid Tumors

Phase 1 Recruiting

38 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06260514 2026-04-23

ACESOT-1051

Phase 1 Recruiting

90 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05036291 2026-04-22

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Phase 1 Terminated

25 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06597721 2026-04-17

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Phase 1 Recruiting

210 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07380334 2026-04-16

A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

200 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06220864 2026-04-14

SNV1521 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

400 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06143774 2026-04-13

Study of TRX-920 for Patients With Advanced Solid Tumors

Phase 1 Recruiting

30 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06352359 2026-04-13

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Phase 1 Recruiting

72 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06130254 2026-04-09

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase 1 Terminated

1 enrolled

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT06422520 2026-04-06

A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

120 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06672185 2026-04-03

ARC101 in Advanced Solid Tumors

Phase 1 Recruiting

70 enrolled

Other solid neoplasm

Advanced Solid Tumor